Compare · NRXS vs OM
NRXS vs OM
Side-by-side comparison of Neuraxis Inc. (NRXS) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NRXS and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- OM carries a market cap of $1.64B.
- Over the past year, NRXS is up 237.3% and OM is down 61.1% - NRXS leads by 298.5 points.
- OM has been more active in the news (6 items in the past 4 weeks vs 5 for NRXS).
- OM has more recent analyst coverage (13 ratings vs 0 for NRXS).
PerformanceNRXS+237.34%OM-61.13%
2025-04-28+0.00%2026-04-24
- Company
- Neuraxis Inc.
- Outset Medical Inc.
- Price
- $7.86+5.93%
- $4.53-0.88%
- Market cap
- -
- $1.64B
- 1M return
- +3.97%
- +28.37%
- 1Y return
- +237.34%
- -61.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- AMEX
- NASDAQ
- IPO
- 2023
- 2020
- News (4w)
- 5
- 6
- Recent ratings
- 0
- 13
OM
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest NRXS
- Neuraxis Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- NeurAxis Expands Payer Coverage with Four New Medical Policies
- Neuraxis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition
- SEC Form 424B5 filed by Neuraxis Inc.
- NeurAxis, Inc. Announces Preferred Stock Dividend
- SEC Form 4 filed by Henrichs Timothy Robert
- SEC Form 4 filed by Carrico Thomas Joeseph
- SEC Form 4 filed by Carrico Brian Allen
- NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results
- SEC Form 10-K filed by Neuraxis Inc.
Latest OM
- SEC Form DEFA14A filed by Outset Medical Inc.
- SEC Form DEF 14A filed by Outset Medical Inc.
- SEC Form 4 filed by Elliott Derick A.
- SEC Form 3 filed by new insider Elliott Derick A.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical Names Derick Elliott as Executive Vice President of Commercial
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)
- General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)
- Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)